Exciting News for the Pericarditis Community!

On March 18, 2021, Kiniksa Pharmaceuticals received approval from the U.S. Food and Drug Administration (FDA) of ARCALYST (rilonacept) for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children 12 years and older.  ARCALYST is the first and only FDA-approved treatment for people living with recurrent pericarditis who are age 12 years or older.  ARCALYST specifically targets the cytokine interleukin-1 (IL-1α and IL-1β), which has been implicated as the driver of inflammation in recurrent pericarditis.  For more information on this product approval, please read our press release here or visit www.ARCALYST.com.

Thank you for your unwavering advocacy on behalf of patients suffering from recurrent pericarditis and their families!  Kiniksa Pharmaceuticals is grateful to the patients, investigators, and study teams who participated in, and contributed to, the conduct of the RHAPSODY clinical trial.  We are also grateful to the patients’ families, caregivers, and advocates who supported them throughout the clinical trial.  We look forward to furthering our partnership to help support the pericarditis community.